This expert consensus project explores the role of low-dose isotretinoin as a rejuvenative and preventive strategy for photoaging and sebaceous-driven skin changes. While isotretinoin is traditionally used for acne, increasing clinical experience suggests that carefully selected micro-dose and low-dose regimens may improve skin texture, pore size, sebaceous activity, and overall skin quality, with potential benefits in skin aging and maintenance rejuvenation programs.
Eligibility
Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Board-certified dermatologists or equivalent.
* 5 years clinical experience in dermatology.
Practical experience prescribing isotretinoin, including low- or micro-dose regimens for rejuvenation or acne.
Active engagement in clinical dermatology, teaching, research, or guideline development.
Willingness to participate in all Delphi rounds and provide informed consent.
Exclusion Criteria:
* Non-dermatology specialists.
Less than 5 years of clinical experience.
Lack of relevant isotretinoin experience.
Significant undisclosed conflict of interest with isotretinoin manufacturers.
Inability to participate in all Delphi rounds.
Primary outcome measure(s)
Primary Outcome — 6-12 weeks Level of expert consensus on statements regarding the use of isotretinoin for skin rejuvenation, measured as the proportion of panelists reaching a predefined agreement threshold (e.g., ≥70-80%) per statement.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.